Model Informed Drug Development Archives

Press Coverage

How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?

Discover how advances in personalized medicine are reshaping patient care, and why biosimulation will become…

CertaraJanuary 31, 2025

Publication

Understanding Variability in CAR-T Cell Therapy Kinetics

Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…

CertaraJanuary 23, 2025

Publication

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical…

CertaraJanuary 14, 2025

On-Demand Webinar

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…

CertaraJanuary 9, 2025

On-Demand Webinar

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

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 SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client…

CertaraJanuary 3, 2025

Poster

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

CertaraDecember 12, 2024

Video

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…

CertaraDecember 10, 2024

Publication

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…

CertaraDecember 9, 2024

Press Coverage

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Published: November 27, 2024 Recent decades have seen continuing declines in pharmaceutical R&D productivity. Inflation…

CertaraNovember 27, 2024

Poster

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

CertaraNovember 22, 2024

Model Informed Drug Development

How do you see advances in personalized medicine reshaping patient care, and what are the key challenges and opportunities ahead?

Understanding Variability in CAR-T Cell Therapy Kinetics

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region

Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA)

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

Population Pharmacokinetics (PopPK) of Revumenib in Patients with Relapsed/Refractory Acute Leukemias

Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development

Advancing pharmacometrics in Africa – Transition from capacity development toward job creation

Forbes: Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi

Newsletter sign up

Quick links

Solutions

Contact